Craig A. Hunter, John Glasspool, Rebecca Singer Cohen, Abdulkadir Keskinaslan
언어
영어(ENG)
URL
https://www.earticle.net/Article/A148349
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
영어
Objective: To summarize and analyze the available literature around risk-sharing agreements and related concepts. Summary: As both payers and manufactures continue to try and maximize the value of new pharmaceutical technologies, it has become increasingly clear that the previous methods of in-market evidence generation and review have been insufficient, proving to be too costly, time consuming, and removed from real-world aspects of treatment. To counter these limitations, risk-sharing agreements have been proposed as a way to develop evidence for the market (once safety is proven) while still offering incentives to manufactures to continually develop new technology. Manufacturers can use the agreements to first get covered within a market, and then to build trust and good faith in their products with payers by proving their therapeutic value via real-world evidence collection. This literature review summarizes the available literature on the topic of risk-sharing agreements and provides key examples of agreements that were previously signed.
목차
Abstract Introduction Definitions Approaches to Implementation Analysis of Current and Past Agreements Summary Special Thanks References
한국보건사회약료경영학회 [Korean Academy of Social & Managed Care Phemacy]
설립연도
2009
분야
의약학>약학
소개
본 학회는 비영리 학술단체로서 환자의 삶의 질 향상을 위한 약료(pharmaceutical care)가 보장될 수 있도록 약료경영약학(managed care pharmacy)을 발전시키는 데 궁극 목적을 두고 다음과 같은 활동을 전개하여 사회에 기여하며 회원 상호간의 친목을 도모한다.
간행물
간행물명
한국보건사회약료경영학회지 [Journal of Korean Academy of Managed Care Pharmacy]